The new Veriqa module RT MonteCarlo 3D, which uses the SciMoCa dose engine for calculation-based radiotherapy plan verification, has received CE mark approval and is now available for sale in Europe and other global markets.
Veriqa RT MonteCarlo 3D provides accurate verification of patient treatment plans based on independent dose calculations. Using the well-established Monte Carlo method, which is regarded as the gold standard for dose calculation among medical physicists, Veriqa RT MonteCarlo 3D recalculates the dose in the patient geometry and automatically compares it with the planned dose. Calculation results are available in a few minutes, requiring minimum user interaction and saving radiation oncology departments valuable time in daily quality assurance.
'Is it safe?'
Communicating radiation risks is not only a legal requirement, it is also a moral obligation, asserts Dr Shane J Foley, radiographer and assistant professor at the UCD School of Medicine in Dublin, Ireland. Passing on radiation information has its pitfalls, but several helpful tools can improve communication, some of which the expert highlighted during ECR 2018.
The accuracy of Radialogica’s SciMoCa Monte Carlo algorithm is widely recognized and has been validated in numerous clinical studies and publications. “When we decided to enhance our Veriqa platform with Monte Carlo calculations, we were looking for a partner who would complement our expertise and meet our high quality standards”, says Dr. Tobias Schüle, managing director of PTW. “Through the partnership with Radialogica we are advancing the development of our workflow-oriented software solutions for quality assurance in radiotherapy.”
The Chief Executive Officer of Radialogica, Andrew Cowen, is also happy about the collaboration: “We are delighted to partner with PTW to integrate the SciMoCa dose calculation algorithm as part of the Veriqa platform. PTW has a well-established track record of product leadership and technical expertise in radiotherapy QA and we are pleased to collaborate with them on this important initiative to advance patient care.”
Source: PTW Freiburg GmbH